Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project
Recruiting now · Phase 2
Conditions studied: Adverse Pregnancy Outcome
In brief
The goal of this randomized clinical trial is to evaluate if we can use placental pathology in a prior pregnancy which had an adverse outcome, such as early delivery, stillbirth, a baby born smaller than expected, or severe forms of high blood pressure during pregnancy, to guide treatment in the subsequent pregnancy and reduce risk of recurrent adverse pregnancy events. The main questions it aims to answer are: * Whether enoxaparin prevents recurrent adverse pregnancy outcomes among patients with a prior adverse pregnancy outcome that occurred in the setting of maternal vascular malperfusion (MVM). * If enoxaparin reduces the occurrence or severity of MVM among patients with a prior adverse pregnancy outcome that occurred in the setting of MVM.
Key facts
- Study ID
- NCT06004674
- Run by
- Endeavor Health
- People needed
- 20
- Starts
- 2023-12-26
- Expected to finish
- 2027-03-01
- Last updated by the study team
- 2026-07-23
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.
You may not qualify if…
- Anticoagulation planned for current pregnancy (including warfarin, enoxaparin, heparin)
- Known major fetal anomaly
- Contraindication to enoxaparin: Specifically active major bleeding, known thrombocytopenia (platelets <100), hypersensitivity to enoxaparin sodium, hypersensitivity to heparin or pork products, hypersensitivity to benzyl alcohol
- Chronic kidney disease with eGFR< 60
- Known chronic liver disease with baseline AST/ALT > 3 x upper limit of normal
- Subjects with mechanical prosthetic heart valves
Where it is running
- NorthShore University HealthSystem — Evanston, Illinois, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.